Autoimmune hepatitis is an independent risk factor for allograft loss and morbidity after liver transplantation: evidence from the Swiss Transplant Cohort Study
BACKGROUND: Liver transplantation is the only curative option for end-stage autoimmune hepatitis (AIH). Although overall outcomes are favourable, previous studies suggest an increased risk of allograft loss and mortality in this population. We assessed post-liver transplantation outcomes in AIH recipients using data from the nationwide multicentre Swiss Transplant Cohort Study (STCS). METHODS: We included all adult patients undergoing a first liver transplantation between May 2008 and December 2020. Indications were categorised as AIH, alcohol-related liver disease, viral liver disease, primary biliary cholangitis, primary sclerosing cholangitis, metabolic dysfunction-associated liver disease or other/mixed aetiologies. Survival analyses and multivariable competing risk Cox models were applied. Clinical Registration number (CER-VD): 2021-01982. RESULTS: Among 880 liver transplantation recipients, 23 (2.6%) underwent liver transplantation for AIH. The 1-, 5- and 10-year post-liver transplantation survival rates in the AIH group were 87.0%, 76.5% and 76.5%, respectively – comparable to other indications. Allograft failure occurred in 34.8% of AIH recipients, significantly more often than in alcohol-related liver disease (8.3%, p <0.001), viral liver disease (13.5%, p = 0.003), primary sclerosing cholangitis (12.2%, p = 0.029) and metabolic dysfunction-associated liver disease (8.2%, p = 0.005). On multivariable analysis, AIH remained independently associated with increased allograft loss (HR 4.23, 95% CI 1.85–9.64; p = 0.003). Hepatic artery thrombosis occurred in 4/23 AIH patients and caused early allograft failure in all cases. CONCLUSION: Despite comparable long-term survival, AIH recipients had a higher risk of early allograft loss, with vascular complications contributing to several early failures. Although the small AIH sample limited the precision of the estimated effects, these findings suggest the need for tailored pre- and post-transplant surveillance with particular attention to vascular complications.
Authors
- Julien Vionnet (ORCID: https://orcid.org/0000-0002-1654-0488)
- Linard Hoessly (ORCID: https://orcid.org/0000-0002-2745-2141)
- Markus Hermann Heim (ORCID: https://orcid.org/0000-0002-7523-4894)
- G. Magini
- M. Pascual
- Beat Müllhaupt (ORCID: https://orcid.org/0000-0002-9020-8192)
- José Oberholzer (ORCID: https://orcid.org/0000-0002-1069-2501)
- Nasser Semmo (ORCID: https://orcid.org/0000-0003-2707-765X)
- Mirjam Kolev (ORCID: https://orcid.org/0000-0002-5027-3432)
- Susanne Stampf (ORCID: https://orcid.org/0000-0003-3399-5078)
- Darius Moradpour (ORCID: https://orcid.org/0000-0003-1977-6792)
- Nicolas Goossens (ORCID: https://orcid.org/0000-0002-8698-4690)
- David Semela (ORCID: https://orcid.org/0000-0002-7201-743X)
- the Swiss Transplant Cohort Study (ORCID: https://orcid.org/0000-0002-6369-819X)
- Aurélie Rosat
- Montserrat Fraga
- Andreas Kremer
- Vanessa Banz
- Benedetta Terziroli Beretta-Piccoli
- Philippe Compagnon
- Simon Brunner
- Annalisa Berzigotti
- Michael Koller
Institutions
- University of Bern (CH)
- University of Basel (CH)
- University of Zurich (CH)
- Kantonsspital St. Gallen (CH)
- University Hospital of Bern (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- University Hospital of Basel (CH)
- Ente Ospedaliero Cantonale (CH)
- University Hospital of Zurich (CH)
- University Hospital of Geneva (CH)
- Kantonsspital Graubünden (CH)
- Università della Svizzera italiana (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- Swiss Medical Weekly
- Published
- 2026-11-16
- DOI
- https://doi.org/10.57187/5375
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Université de Lausanne
- Swiss Transplant Cohort Study